Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.
Selkoe
Dennis J
DJ
Center for Neurologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Harvard Institutes of Medicine, Boston, Massachusetts 02115, USA. selkoe@cnd.bwh.harvard.edu
D000544:Alzheimer Disease / Q000209:etiology / Q000235:genetics* / Q000378:metabolism* / Q000628:therapy; D000595:Amino Acid Sequence; D053829:Amyloid Precursor Protein Secretases; D016229:Amyloid beta-Peptides / Q000235:genetics* / Q000378:metabolism*; D000818:Animals; D016282:Aspartic Acid Endopeptidases; D001921:Brain / Q000378:metabolism; D010450:Endopeptidases / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D008954:Models, Biological; D008969:Molecular Sequence Data; D009154:Mutation; D053764:Presenilin-1; D053766:Presenilin-2; D051880:Receptors, Notch
D016229:Amyloid beta-Peptides; D008565:Membrane Proteins; C508853:PSEN1 protein, human; C508861:PSEN2 protein, human; D053764:Presenilin-1; D053766:Presenilin-2; D051880:Receptors, Notch; D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human